Bacteriological and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants

K. Sunakawa, Y. Ishizuka, N. Saito, H. Akita, S. Iwata, Y. Sato, T. Oikawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The antimicrobial activity of imipenem against group B streptococci was investigated. The clinical efficacy of imipenem/cilastatin sodium (IPM/CS) was determined in neonates and premature infants. The results are summarized below. 1. The distribution of MIC values of IPM against 55 clinical isolates of group B streptococci isolated from the vagina of pregnant women peaked at 0.024 μg/ml. MIC values of IPM against all clinical isolates tested were 0.05 μg/ml or less. 2. IPM/CS was used for treatment of bacterial infections in 9 neonates and premature infants. Among these patients, clinical responses were excellent in 5 patients and good in 4 patients. No adverse reaction was observed. Abnormal laboratory test values were observed in 4 patients, eosinophilia in 2 patients and increased platelets in 2. 3. In 7 neonates and premature infants, quantitative cultures for aerobic and anaerobic fecal flora were performed. Fecal flora change was not significantly different than those observed during treatment with latamoxef or cefmenoxime. 4. Ten neonates and premature infants were investigated for effects of IPM/CS on the blood coagulation system. Prolongations of prothrombin time (PT) and activated partial thromboplastin time (APTT) were observed in 1 patient. Abnormal prothrombin (PIVKA II) was detected in the same patient. There was no tendency for inhibition of platelet function.

Original languageEnglish
Pages (from-to)1692-1703
Number of pages12
JournalJapanese Journal of Antibiotics
Volume41
Issue number11
Publication statusPublished - 1988

Fingerprint

Cilastatin
Premature Infants
Newborn Infant
Streptococcus agalactiae
Blood Platelets
Cefmenoxime
Moxalactam
Partial Thromboplastin Time
Imipenem
Prothrombin Time
Eosinophilia
Prothrombin
Blood Coagulation
Vagina
imipenem drug combination cilastatin
Bacterial Infections
Pregnant Women
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Sunakawa, K., Ishizuka, Y., Saito, N., Akita, H., Iwata, S., Sato, Y., & Oikawa, T. (1988). Bacteriological and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants. Japanese Journal of Antibiotics, 41(11), 1692-1703.

Bacteriological and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants. / Sunakawa, K.; Ishizuka, Y.; Saito, N.; Akita, H.; Iwata, S.; Sato, Y.; Oikawa, T.

In: Japanese Journal of Antibiotics, Vol. 41, No. 11, 1988, p. 1692-1703.

Research output: Contribution to journalArticle

Sunakawa, K, Ishizuka, Y, Saito, N, Akita, H, Iwata, S, Sato, Y & Oikawa, T 1988, 'Bacteriological and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants', Japanese Journal of Antibiotics, vol. 41, no. 11, pp. 1692-1703.
Sunakawa K, Ishizuka Y, Saito N, Akita H, Iwata S, Sato Y et al. Bacteriological and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants. Japanese Journal of Antibiotics. 1988;41(11):1692-1703.
Sunakawa, K. ; Ishizuka, Y. ; Saito, N. ; Akita, H. ; Iwata, S. ; Sato, Y. ; Oikawa, T. / Bacteriological and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants. In: Japanese Journal of Antibiotics. 1988 ; Vol. 41, No. 11. pp. 1692-1703.
@article{0eb53797c810480eac00a19d48a9df16,
title = "Bacteriological and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants",
abstract = "The antimicrobial activity of imipenem against group B streptococci was investigated. The clinical efficacy of imipenem/cilastatin sodium (IPM/CS) was determined in neonates and premature infants. The results are summarized below. 1. The distribution of MIC values of IPM against 55 clinical isolates of group B streptococci isolated from the vagina of pregnant women peaked at 0.024 μg/ml. MIC values of IPM against all clinical isolates tested were 0.05 μg/ml or less. 2. IPM/CS was used for treatment of bacterial infections in 9 neonates and premature infants. Among these patients, clinical responses were excellent in 5 patients and good in 4 patients. No adverse reaction was observed. Abnormal laboratory test values were observed in 4 patients, eosinophilia in 2 patients and increased platelets in 2. 3. In 7 neonates and premature infants, quantitative cultures for aerobic and anaerobic fecal flora were performed. Fecal flora change was not significantly different than those observed during treatment with latamoxef or cefmenoxime. 4. Ten neonates and premature infants were investigated for effects of IPM/CS on the blood coagulation system. Prolongations of prothrombin time (PT) and activated partial thromboplastin time (APTT) were observed in 1 patient. Abnormal prothrombin (PIVKA II) was detected in the same patient. There was no tendency for inhibition of platelet function.",
author = "K. Sunakawa and Y. Ishizuka and N. Saito and H. Akita and S. Iwata and Y. Sato and T. Oikawa",
year = "1988",
language = "English",
volume = "41",
pages = "1692--1703",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "11",

}

TY - JOUR

T1 - Bacteriological and clinical evaluations of imipenem/cilastatin sodium in neonates and premature infants

AU - Sunakawa, K.

AU - Ishizuka, Y.

AU - Saito, N.

AU - Akita, H.

AU - Iwata, S.

AU - Sato, Y.

AU - Oikawa, T.

PY - 1988

Y1 - 1988

N2 - The antimicrobial activity of imipenem against group B streptococci was investigated. The clinical efficacy of imipenem/cilastatin sodium (IPM/CS) was determined in neonates and premature infants. The results are summarized below. 1. The distribution of MIC values of IPM against 55 clinical isolates of group B streptococci isolated from the vagina of pregnant women peaked at 0.024 μg/ml. MIC values of IPM against all clinical isolates tested were 0.05 μg/ml or less. 2. IPM/CS was used for treatment of bacterial infections in 9 neonates and premature infants. Among these patients, clinical responses were excellent in 5 patients and good in 4 patients. No adverse reaction was observed. Abnormal laboratory test values were observed in 4 patients, eosinophilia in 2 patients and increased platelets in 2. 3. In 7 neonates and premature infants, quantitative cultures for aerobic and anaerobic fecal flora were performed. Fecal flora change was not significantly different than those observed during treatment with latamoxef or cefmenoxime. 4. Ten neonates and premature infants were investigated for effects of IPM/CS on the blood coagulation system. Prolongations of prothrombin time (PT) and activated partial thromboplastin time (APTT) were observed in 1 patient. Abnormal prothrombin (PIVKA II) was detected in the same patient. There was no tendency for inhibition of platelet function.

AB - The antimicrobial activity of imipenem against group B streptococci was investigated. The clinical efficacy of imipenem/cilastatin sodium (IPM/CS) was determined in neonates and premature infants. The results are summarized below. 1. The distribution of MIC values of IPM against 55 clinical isolates of group B streptococci isolated from the vagina of pregnant women peaked at 0.024 μg/ml. MIC values of IPM against all clinical isolates tested were 0.05 μg/ml or less. 2. IPM/CS was used for treatment of bacterial infections in 9 neonates and premature infants. Among these patients, clinical responses were excellent in 5 patients and good in 4 patients. No adverse reaction was observed. Abnormal laboratory test values were observed in 4 patients, eosinophilia in 2 patients and increased platelets in 2. 3. In 7 neonates and premature infants, quantitative cultures for aerobic and anaerobic fecal flora were performed. Fecal flora change was not significantly different than those observed during treatment with latamoxef or cefmenoxime. 4. Ten neonates and premature infants were investigated for effects of IPM/CS on the blood coagulation system. Prolongations of prothrombin time (PT) and activated partial thromboplastin time (APTT) were observed in 1 patient. Abnormal prothrombin (PIVKA II) was detected in the same patient. There was no tendency for inhibition of platelet function.

UR - http://www.scopus.com/inward/record.url?scp=0023743950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023743950&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 1692

EP - 1703

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 11

ER -